A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155371 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Ying Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine Center, Sanmenxia Central Hospital, Sanmenxia, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Indoles. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with BRAF V600E mutation-positive NSCLC. Nevertheless, the treatment strategy for NSCLC patients with BRAF non-V600E mutations remains limited. CASE PRESENTATION: Here, we present a NSCLC patient with a BRAF N581S mutation, which is a class III BRAF mutation, and this patient had a durable response to targeted therapy with combined anlotinib and tislelizumab. CONCLUSION: We hope to bring more attention to rare non-V600 BRAF mutations by presenting this case of NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine Center, Sanmenxia Central Hospital, Sanmenxia, China.
- State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
- Department of Traditional Chinese Medicine, Sanmenxia Central Hospital, Sanmenxia, China.
- Department of Statistics Branch, Sanmenxia Central Hospital, Sanmenxia, China.
- Department of Oncology, Sanmenxia Central Hospital, Sanmenxia, China.
- Department of Reproductive Medicine, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China. Electronic address: 361400283@qq.com.
Zitieren
APA
Liu, Y., Li, M., Guo, Y., Zhang, Z., Du, L., Zhang, X., Wang, Y., Zhang, D., Xue, L., Lei, B., Su, J., Zhang, R., Chen, J., Zhang, X., Jia, Q., & Tian, C. (2024). A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155371
Vancouver
Liu Y, Li M, Guo Y, Zhang Z, Du L, Zhang X, et al. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155371
BibTeX
@article{Liu2024,
author = {Liu, Ying and Li, Mingyang and Guo, Yu and Zhang, Zhiyong and Du, Liuyang and Zhang, Xiaotong and Wang, Yingping and Zhang, Dong and Xue, Lingfei and Lei, Binhua and Su, Jing and Zhang, Ruiwen and Chen, Jiaohong and Zhang, Xiangqian and Jia, Qingge and Tian, Chuntao},
title = {A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155371}
}
EUVIMED